Therapeutic capabilities of secnidazole in the treatment of bacterial vaginosis
DOI: 10.32364/2618-8430-2022-5-4-297-302
Yu.E. Dobrokhotova, P.A. Shadrova
Pirogov Russian National Research Medical University, Moscow, Russian Federation
Background: the research is still focused on bacterial vaginosis (BV) in view of its high prevalence among women and potential damaging effects on fertility. The treatment regimens which are presented in the current guidelines and available for obstetricians and gynecologists may cause adverse local and systemic effects. In addition, female patients frequently experience BV recurrences.
Aim: to assess the efficacy of taking secnidazole once as a single dose in the treatment of BV based on clinical findings and laboratory-based test results.
Patients and Methods: the study included 40 female patients with diagnosed BV. The patients were split into two groups, 20 women in each group. The treatment group patients received secnidazole 2 g once as a single dose, and the control group patients received the standard treatment with metronidazole 500 mg twice daily for 7 days. The evaluation of patients included the vaginal pH value and laboratory-based diagnostic tests, such as microscopy of the vaginal discharge and Florocenosis/Bacterial vaginosis-FRT PCR assay whose prognostic value indicators are comparable with the international clinical and laboratory-based diagnostic criteria.
Results: before therapy, the mean leucocyte count in the vaginal smear in the treatment group patients was 12.4±3.0 per field of vision and in the control group patients — 11.3±1.8; after therapy — 9.2±1.2 and 10.1±4.4, respectively. A statistically significant decrease (р<0.05) in vaginal pH was recorded after the therapy: to 4.4±0.1 in the treatment group and 4.3±0.1 in the control group. The average concentration of BV-associated species after the administered therapy was lower than that at the baseline (the difference was statistically significant).
Conclusion: сonsidering the comparable clinical and microbiological outcomes of the alternative and standard BV treatment regimens, as well as the convenience of administration associated with single-dose therapy, secnidazole can be used to treat bacterial vaginosis.
Keywords: bacterial vaginosis, microbiota, pelvic inflammatory disease, secnidazole, metronidazole.
For citation: Dobrokhotova Yu.E., Shadrova P.A. Therapeutic capabilities of secnidazole in the treatment of bacterial vaginosis. Russian Journal of Woman and Child Health. 2022;5(4):297–302 (in Russ.). DOI: 10.32364/2618-8430-2022-5-4-297-302.
About the authors:
Yulia E. Dobrokhotova — Dr. Sc. (Med.), Professor, Head of the Department of Obstetrics & Gynecology of the Medical Faculty, Pirogov Russian National Research Medical University; 1, Ostrovityanova str., Moscow, 117997, Russian Federation; ORCID iD 0000-0002-7830-2290.
Polina A. Shadrova — postgraduate student of the Department of Obstetrics & Gynecology of the Medical Faculty, Pirogov Russian National Research Medical University; 1, Ostrovityanova str., Moscow, 117997, Russian Federation; ORCID iD 0000-0002-3721-1421. Contact information: Polina A. Shadrova, e-mail: shadrovapolina@hotmail.com.
Financial Disclosure: no authors have a financial or property interest in any material or method mentioned.
There is no conflict of interests.
Received 21.09.2022.
Revised 14.10.2022.
Accepted 09.11.2022.
2. Gibbs R.S., Karlah B.Y., Haney A.F., Nygaard I.E. Danforth’s Obstetrics and Gynecology.10th ed. Philadelphia: Lippincott Williams and Wilkins; 2008:625–640.
3. Kira E.F. Bacterial vaginosis. Ed. 2nded. M.: MIA; 2012 (in Russ.).
4. Clinical guidelines. Bacterial vaginosis. 2022 (in Russ.).
5. Amabebe E., Anumba DOC. The Vaginal Microenvironment: The Physiologic Role of Lactobacilli. Front Med (Lausanne). 2018;5:181. DOI: 10.3389/fmed.2018.00181.
6. Lamont R.F., Sobel J.D., Akins R.A. et al. The vaginal microbiome: new information about genital tract flora using molecular based techniques. BJOG. 2011;118(5):533–549. DOI: 10.1111/j.1471-0528.2010.02840.x.
7. Abou Chacra L., Fenollar F., Diop K. Bacterial Vaginosis: What Do We Currently Know? Front Cell Infect Microbiol. 2022;11:672429. DOI: 10.3389/fcimb.2021.672429.
8. Van Oostrum N., De Sutter P., Meys J., Verstraelen H. Risks associated with bacterial vaginosis in infertility patients: a systematic review and meta-analysis. Hum Reprod. 2013;28(7):1809–1815. DOI: 10.1093/humrep/det096.
9. Verstraelen H., Verhelst R., Vaneechoutte M., Temmerman M. The epidemiology of bacterial vaginosis in relation to sexual behaviour. BMC Infect Dis. 2010;10:81. DOI: 10.1186/1471-2334-10-81.
10. Sobel J.D., ed. Bacterial Vaginosis. Waltham, MA: UptoDate 2013. (Electronic resource.) URL: www.uptodate.com/contents/bacterialvaginosis?topicKey=OBGYN%2F5451&elap (access date: 05.09.2022).
11. Sexually Transmitted Infections Treatment Guidelines, 2021. Bacterial vaginosis. (Electronic resource.) URL: https://www.cdc.gov/std/treatment-guidelines/bv.htm (access date: 05.09.2022).
12. Bezhenar V.F., Molchanov O.L., Lazareva N.B. et al. Efficacy of secnidazole in the treatment of trichomoniasis and vaginal dysbiosis. Meditsinskiy Sovet. 2022;16(5):144–151 (in Russ.). DOI: 10.21518/2079-701X-2022-16-5-144-151.
13. Amsel R., Totten P.A., Spiegel C.A. et al. Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiologic associations. Am J Med. 1983;74(1):14–22. DOI: 10.1016/0002-9343(83)91112-9.
14. Dobrokhotova Yu.E., Bondarenko K.R., Gushchin A.E. The results of the examination of cervical-vaginal microbiota in pregnant women with threatened preterm birth using a real-time polymerase chain reaction. Obstetrics and Gynecology. 2018;(11):50–59 (in Russ.). DOI: 10.18565/aig.2018.11.50-59.
15. Gomberg M.A. Bacterial vaginosis and associated new infections. Russian Bulletin of Obstetrician-Gynecologist. 2010;10(2):32–34 (in Russ.).
16. Faught B.M., Reyes S. Characterization and treatment of recurrent bacterial vaginosis. J Womens Health (Larchmt). 2019;28(9):1218–1226. DOI: 10.1089/jwh.2018.7383.
17. Raether W., Hanel H. Nitroheterocyclic drugs with broad spectrum activity. Parasitol Res. 2003;90(Suppl 1):S19–S39. DOI: 10.1007/s00436-002-0754-9.
18. Thulkar J., Kriplani A., Agarwal N. A comparative study of oral single dose of metronidazole, tinidazole, secnidazole and ornidazole in bacterial vaginosis. Indian J Pharmacol. 2012;44(2):243–245. DOI: 10.4103/0253-7613.93859.
19. Petrina M.A.B., Cosentino L.A., Rabe L.K., Hillier S.L. Susceptibility of bacterial vaginosis (BV)-associated bacteria to secnidazole compared to metronidazole, tinidazole and clindamycin. Anaerobe. 2017:47:115–119. DOI: 10.1016/j.anaerobe.2017.05.005.
20. Swidsinski A., Verstraelen H., Loening-Baucke V. et al. Presence of a polymicrobial endometrial biofilm in patients with bacterial vaginosis. PLoS One. 2013;8(1):e53997. DOI: 10.1371/journal.pone.0053997.
21. Guo Y.L., You K., Qiao J. et al. Bacterial vaginosis is conducive to the persistence of HPV infection. Int J STD AIDS. 2012;23(8):581–584. DOI: 10.1258/ijsa.2012.011342.
22. Mirzaeei S., Zangeneh M., Veisi F. et al. Chlorhexidine, clotrimazole, metronidazole and combination therapy in the treatment of vaginal infections. J Med Life. 2021;14(2):250–256. DOI: 10.25122/jml-2019-0160.
23. Hillier S.L., Nyirjesy P., Waldbaum A.S. et al. Secnidazole Treatment of Bacterial Vaginosis: A Randomized Controlled Trial. Obstetrics and gynecology. 2017:130(2):379–386. DOI: 10.1097/AOG.0000000000002135.
This work is licensed under a Creative Commons «Attribution» 4.0 License.
